Experimental animal models of pancreatic carcinogenesis for prevention studies and their relevance to human disease

Cancers

Volumn 3, Issue 1, 2011, Pages 582-602

  Takahashi, Mami ^a   Hori, Mika ^a   Mutoh, Michihiro ^a   Wakabayashi, Keiji ^b   Nakagama, Hitoshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

BOP; Hamster; Hyperlipidemia; iNOS; Pancreatic cancer

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 7 CHLORO 3 IMINO 5 METHYL 2 AZABICYCLO[4.1.0]HEPTANE; ACETYLSALICYLIC ACID; BUTYLATED HYDROXYANISOLE; CELECOXIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2 INHIBITOR; DASATINIB; FRAGILE HISTIDINE TRIAD PROTEIN; GEFITINIB; IBUPROFEN; INDOMETACIN; K RAS PROTEIN; METFORMIN; METHIONINE; NIMESULIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROSAMINE; OLTIPRAZ; PHENETHYL ISOTHIOCYANATE; PHENYLBUTAZONE; PIOGLITAZONE; PROTEIN P16; PROTEIN P53; PROTOCATECHUIC ACID; SARCOPHYTOL A; SMAD4 PROTEIN; SULFORAPHANE; UNINDEXED DRUG; ZILEUTON;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CARCINOGENESIS; CHEMICAL CARCINOGENESIS; CHRONIC INFLAMMATION; CPG ISLAND; DIABETES MELLITUS; EXPERIMENTAL MODEL; GENE DELETION; GENETIC SIMILARITY; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; LIVER METASTASIS; NONHUMAN; OBESITY; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATITIS; POINT MUTATION; REVIEW; RISK FACTOR; SYRIAN HAMSTER;

EID: 79953719071     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010582     Document Type: Review

References (155)

1. Matsuno, S.; Egawa, S.; Shibuya, K.; Shimamura, H.; Sunamura, M.; Takeda, K.; Katoh, H.; Okada, S.; Suda, K.; Nakao, A.; Isaji, S.; Hiraoka, T.; Hosotani, R.; Imaizumi, T. Pancreatic cancer: Current status of treatment and survival of 16071 patients diagnosed from 1981-1996, using the Japanese National Pancreatic Cancer Database. Int. J. Clin. Oncol. 2000, 5, 153-157.
2. Standop, J.; Schneider, M.B.; Ulrich, A.; Pour, P.M. Experimental animal models in pancreatic carcinogenesis: Lessons for human pancreatic cancer. Dig. Dis. 2001, 19, 24-31.
3. Pour, P.; Kruger, F.W.; Althoff, J.; Cardesa, A.; Mohr, U. Cancer of the pancreas induced in the Syrian golden hamster. Am. J. Pathol. 1974, 76, 349-358.
4. Pour, P.; Althoff, J.; Krüger, F.W.; Mohr, U. A potent pancreatic carcinogen in Syrian hamsters: N-nitrosobis(2-oxopropyl)amine. J. Natl. Cancer Inst. 1977, 58, 1449-1453.
5. Pour, P. Experimental pancreatic ductal (ductular) tumors. Monogr. Pathol. 1980, 21, 111-139.
6. Pour, P.M.; Runge, R.G.; Birt, D.; Gingell, R.; Lawson, T.; Nagel, D.; Wallcave, L.; Salmasi, A.H. Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to the human disease. Cancer 1981, 47, 1573-1587.
7. Pour, P.; Althoff, J.; Takahashi, M. Early lesions of pancreatic ductal carcinoma in the hamster model. Am. J. Pathol. 1977, 88, 291-308.
8. Schüller, H.M.; Jorquera, R.; Reichert, A.; Castonguay, A. Transplacental induction of pancreas tumors in hamsters by ethanol and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 1993, 53, 2498-2501.
9. Longnecker, D.S.; Curphey, T.J. Adenocarcinoma of the pancreas in azaserine-treated rats. Cancer Res. 1975, 35, 2249-2258.
10. Longnecker, D.S.; Curphey, T.J.; Lilja, H.S.; French, J.I.; Daniel, D.S. Carcinogenicity in rats of the nitrosourea amino acid N delta-(N-methyl-N-nitrosocarbamoyl)-L-ornithine. Environ. Pathol. Toxicol. 1980, 4, 117-129.
11. Longnecker, D.S.; Curphey, T.J.; Kuhlmann, E.T.; Schaeffer, B.K. Experimental induction of pancreatic carcinomas in the hamster with N delta-(N-methyl-N-nitrosocarbamoyl)-L-ornithine. J. Natl. Cancer Inst. 1983, 71, 1327-1336.
12. Pour, P.; Salmasi, S.; Runge, R.; Gingell, R.; Wallcave, L.; Nagel, D.; Stepan, K. Carcinogenicity of N-nitrosobis(2-hydroxypropyl)amine and N-nitrosobis(2-oxopropyl)amine in MRC rats. J. Natl. Cancer Inst. 1979, 63, 181-190.
13. Sakano, K.; Takahashi, M.; Mutoh, M.; Niho, N.; Komiya, M.; Sato, H.; Tanaka, T.; Sugimura, T.; Wakabayashi, K. Enhanced thyroid carcinogenicity of N-nitrosobis(2-oxopropyl)amine in Otsuka Long-Evans Tokushima Fatty rats, a model of type II diabetes mellitus. Carcinogenesis 2007, 28, 2193-2198.
14. Fujii, K.; Hayakawa, T.; Kikuchi, M. Tumor induction in mice administered neonatally with bis(2-oxopropyl)nitrosamine. Tohoku J. Exp. Med. 1994, 174, 361-368.
15. Scarpelli, D.G.; Rao, M.S.; Reddy, J.K. Studies of pancreatic carcinogenesis in different animal models. Environ. Health Persp. 1984, 56, 219-227.
16. Rao, M.S. Animal models of exocrine pancreatic carcinogenesis. Cancer Metast. Rev. 1987, 6, 665-676.
17. Longnecker, D. Experimental pancreatic cancer: Role of species, sex and diet. Bull. Cancer 1990, 77, 27-37.
18. Dissin, J.; Mills, L.R.; Mains, D.L.; Black, O., Jr.; Webster, P.D., 3rd. Experimental induction of pancreatic adenocarcinoma in rats. J. Natl. Cancer Inst. 1975, 55, 857-864.
19. Bockman, D.E.; Black, O., Jr.; Mills, L.R.; Mainz, D.L.; Webster, P.D. 3rd. Fine structure of pancreatic adenocarcinoma induced in rats by 7,12-dimethylbenz(a)anthracene. J. Natl. Cancer Inst. 1976, 57, 931-936.
20. Osvaldt, A.B.; Wendt, L.R.; Bersch, V.P.; Backes, A.N.; de Cássia, A.; Schumacher, R.; Edelweiss, M.I.; Rohde, L. Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice. Surgery 2006, 140, 803-809.
21. Jimenez, R.E.; Z'graggen, K.; Hartwig, W.; Graeme-Cook, F.; Warshaw, A.L.; Castillo, C.F. Immunohistochemical characterization of pancreatic tumors induced by dimethylbenzanthracene in rats. Am. J. Pathol. 1999, 154, 1223-1229.
22. Z'graggen K.; Warshaw, A.L.; Welner, J.; Graeme-Cook, F.; Jimenez, R.E.; Castillo, C.F. Promoting effects of a high-fat/high-protein diet in DMBA-induced ductal pancreatic cancer in rats. Ann. Surgery 2001, 233, 688-695.
23. Hruban, R.H.; Adsay, N.V.; Albores-Saavedra, J.; Anver, M.R.; Biankin, A.V.; Boivin, G.P.; Furth, E.E.; Furukawa, T.; Klein, A.; Klimstra, D.S.; Kloppel, G.; Lauwers, G.Y.; Longnecker, D.S.; Luttges, J.; Maitra, A.; Offerhaus, G.J.; Pérez-Gallego, L.; Redston, M.; Tuveson, D.A. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendations. Cancer Res. 2006, 66, 95-106.
24. Grippo, P.J.; Nowlin, P.S.; Demeure, M.J.; Longnecker, D.S.; Sandgren, E.P. Preinvasive pancreatic neooplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenenic mice. Cancer Res. 2003, 63, 2016-2019.
25. Hingorani, S.R.; Petricoin, E.F.; Maitra, A.; Rajapakse, V.; King, C.; Jacobetz, M.A.; Ross, S.; Conrads, T.P.; Veenstra, T.D.; Hitt, B.A.; Kawaguchi, Y.; Johann, D.; Liotta, L.A.; Crawford, H.C.; Putt, M.E.; Jacks, T.; Wright, C.V.; Hruban, R.H.; Lowy, A.M.; Tuveson, D.A. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4, 437-450.
26. Deramaudt, T.; Rustgi, A.K. Mutant KRAS in the initiation of pancreatic cancer. Biochem. Biophys. Acta 2005, 1756, 97-101.
27. Aguirre, A.J.; Bardeesy, N.; Sinha, M.; Lopez, L.; Tuveson, D.A.; Horner, J.; Redston, M.S., DePinho, R.A. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adeocarcinoma. Genes & Dev. 2003, 17, 3112-3126.
28. Hingorani, S.R.; Wang, L.; Multani, A.S.; Combs, C.; Deramaudt, T.B.; Hruban, R.H.; Rustgi, A.K.; Chang, S.; Tuveson, D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7, 469-483.
29. Kijima, K.; Vickers, S.M.; Adsay, N.V.; Jhala, N.C.; Kim, H.; Schoeb, T.R.; Grizzle, W.E.; Klug, C.A. Inactivation of Smad4 accelerates KrasG12D-mediated pancreatic neoplasia. Cancer Res. 2007, 67, 8121-8130.
30. Ijichi, H.; Chytil, A.; Gorska, A.E.; Aakre, M.E.; Fujitani, Y.; Fujitani, S.; Wright, C.V.E.; Moses, H.L. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras exoression. Genes Dev. 2006, 20, 3147-3160.
31. Guerra, C.; Schuhmacher, A.J.; Cañamero, M.; Grippo, P.J.; Verdaguer, L.; Pérez-Gallego, L.; Dubus, P.; Sandgren, E.P.; Barbacid, M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11, 291-302.
32. Ueda, S.; Fukamachi, K.; Matsuoka, Y.; Takasuka, N.; Takeshita, F.; Naito, A.; Iigo, M.; Alexander D.B.; Moore, M.A.; Saito, I.; Ochiya, T.; Tsuda, H. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. Carcinogenesis 2006, 27, 2497-2510.
33. Fukamachi, K.; Tanaka, H.; Hagiwara, Y.; Ohara, H.; Joh, T.; Iigo, M.; Alexander, D.B.; Xu, J.; Long, N.; Takigahira, M.; Yanagihara, Y.; Hino, O.; Saito, I.; Tsuda, H. An animal model of preclinical diagnosis of pancreatic ductal carcinomas. Biochem. Biophys. Res. Commun. 2009, 390, 636-641.
34. Hruban, R.H.; Wilentz, R.E.; Kern, S.E. Genetic progression in the pancreatic ducts. Am. J. Pathol. 2000, 156, 1821-1825.
35. Bardeesy, N.; DePinho, R.A. Pancreatic cancer biology and genetics. Nature Rev. 2002, 2, 897-909.
36. Moore, P.; Beghelli, S.; Zamboni, G.; Scarpa, A. Genetic abnormalities in pancreatic cancer. Mol. Cancer 2003, 2, 1-7.
37. Tarafa, G.; Villanueva, A.; Farré, L.; Rodríguez, J., Musulén, E.; Reyes, G.; Seminago, R.; Olmedo, E.; Paules, A.B.; Peinado, M.A.; Bachs, O.; Capellá, G. DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene 2000, 19, 546-555.
38. Konishi, Y.; Tsutsumi, M.; Tsujiuchi, T. Mechanistic analysis of pancreatic ductal carcinogenesis in hamsters. Pancreas 1998, 16, 300-306.
39. Tsujiuchi, T.; Tsutsumi, M.; Konishi, Y. Molecular aspects during multi-step chemical induced carcinogenesis in the lung and pancreas. J. Toxicol. Pathol. 2003, 16, 133-138.
40. van Kranen, H.J.; Vermeulen, E.; Schoren, L.; Bax, J.; Woutersen, R.A.; van Iersel, P.; van Kreijl, C.F.; Scherer, E. Activation of c-K-ras is frequent in pancreatic carcinomas of Syrian hamsters, but is absent in pancreatic tumors of rats. Carcinogenesis 1991, 12, 1477-1482.
41. Cerny, W.L.; Mangold, K.A.; Scarpelli, D.G. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res. 1992, 52, 4507-4513.
42. Chang, K.W.; Laconi, S.; Mangold, K.A.; Hubchak, S.; Scarpelli, D.G. Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas. Cancer Res. 1995, 55, 2560-2568.
43. Burmer, G.C.; Rabinovitch, P.S.; Loeb, L.A. Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. Environ. Health Persp. 1991, 93, 27-31.
44. Mu, D.; Peng, Y.; Xu, Q. Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J. Gastroenterol. 2004, 10, 471-475.
45. Saif, M.W.; Karapanagiotou, L.; Syrigos, K. Genetic alterations in pancreatic cancer. World J. Gastroenterol. 2007, 7, 4423-4430.
46. Terhune, P.G.; Phifer, D.M.; Tosteson, T.D.; Longnecker, D.S. K-ras mutation infocal proliferative lesions of human pancreas. Cancer Epidem. Biomark. Prev. 1998, 7, 515-521.
47. Caldas, C.; Hahn, S.A.; da Costa, L.T.; Redston, M.S.; Schutte, M.; Seymour, A.B.; Weinstein, C.L.; Hruban, R.H.; Yeo, C.J.; Kern, S.E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 1994, 8, 27-32.
48. Hruban, R.H.; Offerhaus, G.J.A.; Kern, S.E.; Goggins, M.; Wilentz, R.E.; Yeo, C.J. Tumor-suppressor genes in pancreatic cancer. J. Hepatobilary Pancreat. Surg. 1998, 5, 383-391.
49. Li, J.; Weghorst, C.M.; Tsutsumi, M.; Poi, M.J.; Knobloch, T.J.; Casto, B.C.; Melvin, W.S.; Tsai, M.; Muscarella, P. Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors. Carcinogenesis 2004, 25, 263-268.
50. Hahn, S.A.; Schutte, M.; Hoque, A.T.; Moskaluk, C.A.; da Costa, L.T.; Rozenblum, E.; Weinstein, C.L.; Fischer, A.; Yeo, C.J.; Hruban, R.H.; Kern, S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271, 350-353.
51. Shimizu, K.; Kitahashi, T.; Fujii, H.; Tsutsumi, M.; Mori, T.; Honoki, K.; Tsujiuchi, T. Alterations in the Smad4 gene in hamster pancreatic duct adenocarcinomas and established cell lines. Oncol. Rep. 2006, 16, 85-89.
52. Höhne, M.W.; Halatsch, M.E.; Kahl, G.F.; Weinel, R.J. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res. 1992, 52, 2616-2619.
53. Chang, K.W.; Laconi, S.; Mangold, K.A.; Hubchak, S.; Scarpelli, D.G. Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas. Cancer Res. 1995, 55, 2560-1568.
54. Barton, C.M.; Staddon, S.L.; Hughes, C.M.; Hall, P.A.; O'Sullivan, C.; Klöppel, G.; Theis, B.; Russell, R.C.; Neoptolemos, J.; Williamson, R.C.; Lane, D.P.; Lemoine, N.R. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer 1991, 64, 1076-1082.
55. Ruggeri, B.; Zhang, S.Y.; Caamano, J.; DiRado, M.; Flynn, S.D.; Klein-Szanto, A.J. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992, 7, 1503-1511.
56. Rozenblum, E.; Schutte, M.; Goggins, M.; Hahn, S.A.; Panzer, S.; Zahurak, M.; Goodman, S.N.; Sohn, T.A.; Hruban, R.H.; Yeo, C.J.; Kern, S.E. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997, 57, 1731-1734.
57. Okita, S.; Tsutsumi, M.; Onji, M.; Konishi, Y. p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters. Mol. Carcinog. 1995, 13, 266-271.
58. Sorio, C.; Baron, A.; Orlandini, S.; Zamboni, G.; Pederzoli, P.; Huebner, K.; Scarpa, A. The FHIT gene is expressed in pancreatic ductular dells and is altered in pancreatic cancers. Cancer Res. 1999, 59, 1308-1314.
59. Gopalakrishnan, V.K.; Banerjee, A.G.; Vishwanatha, J.K. Effect of FHIT gene replacement on growth, cell cycle and apoptosis in pancreatic cancer cells. Pancreatol. 2003, 3, 293-302.
60. Tsijiuchi, T.; Sasaki, Y.; Kubozoe, T.; Konishi, Y.; Tsutsumi, M. Alterations in the Fhit gene in pancreatic duct adenocarcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters. Mol. Carcinog. 2003, 36, 60-66.
61. Kobitsu, K.; Tsutsumi, M.; Tsujiuchi, T.; Suzuki, F.; Kido, A.; Okajima, E.; Fukuda, T.; Sakaki, T.; Konishi, Y. Shortened telomere length and increased telomerase activity in hamster pancreatic duct adeenocarcinomas and cell line. Mol. Carcinog. 1997, 18, 153-159.
62. Hiyama, E.; Kodama, T.; Shinbara, K.; Iwao, T.; Itoh, M.; Hiyama, K.; Shay, J.W.; Matsuura, Y.; Yokoyama, T. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res. 1997, 57, 326-331.
63. Tsutsumi, M.; Kadomatsu, K.; Tsujiuchi, T.; Sakitani, H.; Ikematsu, S.; Kubozoe, T.; Yoshimoto, M.; Marumatsu, T.; Sakuma, S.; Konishi, Y. Overexpression of midkine in pancreatic duct adenocarcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters and their cell line. Jpn. J. Cancer Res. 2000, 91, 979-986.
64. Tsutsui, J.; Kadomatsu, K.; Matsubara, S.; Nakagawara, A.; Hamanoue, M.; Kakao, S.; Shimazu, H.; Ohi, Y.; Muramatsu, T. A new family of heparin-binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res. 1993, 53, 1281-1285.
65. Crowell, P.L.; Schmidt, C.M.; Yip-Schneider, M.T.; Savage, J.J.; Hertzler, D.A. 2nd; Cummings, W.O. Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. Neoplasia 2006, 8, 437-445.
66. Iki, K.; Tsutsumi, M.; Kido, A.; Sakitani, H.; Takahama, M.; Yoshimoto, M.; Motoyama, M.; Tatsumi, K.; Tsunoda, T.; Konishi, Y. Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1999, 20, 1323-1329.
67. Määttä, M.; Soini, Y.; Liakka, A.; Autio-Harmainen, H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: Implications for tumor progression and clinical prognosis. Clin. Cancer Res. 2000, 6, 2726-2734.
68. Michaud, D.S. Epidemiology of pancreatic cancer. Minerva Chir. 2004, 59, 99-111.
69. Birt, D.F.; Salmasi, S.; Pour, P.M. Enhancement of experimental pancreatic cancer in Syrian golden hamsters by dietary fat. J. Natl. Cancer Inst. 1981, 67, 1327-1332.
70. Birt, D.F.; Julius, A.D.; Dwork, E.; Hanna, T.; White, L.T.; Pour, P.M. Comparison of the effects of dietary beef tallow and corn oil on pancreatic carcinogenesis in the hamster model. Carcinogenesis 1990, 11, 745-748.
71. Heukamp, I.; Kilian, M.; Gregor, J.I.; Kiewert, C.; Schimke, I.; Kristiansen, G.; Walz, M.K.; Jacobi, C.A.; Wenger, F.A. Impact of polyunsaturated fatty acids on hepato-pancreatic prostaglandin and leukotriene concentration in ductal pancreatic cancer-Is there a correlation to tumor growth and liver metastasis? Prostaglandins Leukot. Essent. Fatty Acids 2006, 74, 223-233.
72. Khasawneh, J.; Schulz, M.D.; Walch, A.; Rozman, J.; Hrabe de Angelis, M.; Klingenspor, M.; Buck, A.; Schwaiger, M; Saur, D.; Schmid, R.M.; Klöppel, G.; Sipos, B.; Greten, F.R.; Arkan, M.C. Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc. Natl. Acad. Sci. USA 2009, 106, 3354-3359.
73. Strouch, M.J.; Ding, Y.; Salabat, M.R.; Melstrom, L.G.; Adrian, K.; Quinn, C.; Pelham, C.; Rao, S.; Adrian, T.E.; Bentrem, D.J.; Grippo, P.J. A high omega-3 fatty acid diet mitigates murine pancreatic precancer development. J. Surg. Res. 2011, 165, 77-81.
74. Boutros, C.; Somasundar, P.; Razzak, A.; Helton, S.; Espat, N.J. Omega-3 fatty acids: Investigation from cytokine regulation to pancreatic cancer gene suppression. Arch. Surg. 2010, 145, 515-520.
75. Pour, P.M.; Patil, K. Modification of pancreatic carcinogenesis in the hamster model. X. Effect of streptozotocin. J. Natl. Cancer Inst. 1983, 71, 1059-1065.
76. Bell, R.H., Jr.; Strayer, D.S. Streptozotocin prevents development of nitrosamine-induced pancreatic cancer in the Syrian hamster. J. Surg. Oncol. 1983, 24, 258-262.
77. Bell, R.H., Jr.; McCullough, P.J.; Pour, P.M. Influence of diabetes on susceptibility to experimental pancreatic cancer. Am. J. Surg. 1988, 155, 159-164.
78. Fisher, W.E.; McCullough, P.J.; Ray, M.B.; Rogers, D.H.; Bell, R.H., Jr. Diabetes enhances growth of pancreatic carcinoma cells. Surgery 1988, 104, 431-436.
79. Zyromski, N.J.; Mathur, A.; Pitt, H.A.; Wade, T.E.; Wang, S.; Nakshatri, P.; Swartz-Basile, D.A.; Nakshatri, H. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery 2009, 146, 258-263.
80. White, P.B.; True, E.M.; Ziegler, K.M.; Wang, S.S.; Swartz-Basile, D.A.; Pitt, H.A.; Zyromski, N.J. Insulin, Leptin, and tumoral adipocytes promote murine pancreatic cancer growth. J. Gastrointest. Surg. 2010, 14, 1888-1893.
81. Satake, K.; Mukai, R.; Kato, Y.; Umeyama, K. Effects of cerulein on the normal pancreas and on experimental pancreatic carcinoma in the Syrian golden hamster. Pancreas 1986, 1, 246-253.
82. Pour, P.M.; Takahashi, M.; Donnelly, T.; Stepan, K. Modification of pancreatic carcinogenesis in the hamster model. IX. Effect of pancreatitis. J. Natl. Cancer Inst. 1983, 71, 607-613.
83. Otsuki, M.; Tashiro, M. 4. Chronic pancreatitis and pancreatic cancer, lifestyle-related diseases. Intern. Med. 2007, 46, 109-113.
84. Go, V.L.W.; Gukovskaya, A.; Pandol, S.J. Alcohol and pancreatic cancer. Alcohol 2005, 35, 205-211.
85. Wendt, L.R.; Osvaldt, A.B.; Bersch, V.P.; Schumacher, R. de C.; Edelweiss, M.I.; Rohde, L. Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice: Effects of alcohol and caffeine. Acta Cir. Bras. 2007, 22, 202-209.
86. Bersch, V.P.; Osvaldt, A.B.; Edelweiss, M.I.; Schumacher, R. de C.; Wendt, L.R.; Abreu, L.P.; Blom, C.B.; Abreu, G.P.; Costa, L.; Piccinini, P.; Rohde, L. Effect of nicotine and cigarette smoke on an experimental model of intraepithelial lesions and pancreatic adenocarcinoma induced by 7,12-dimethylbenzanthracene in mice. Pancreas 2009, 38, 65-70.
87. Mizumoto, K.; Tsutsumi, M.; Denda, A.; Konishi, Y. Rapid production of pancreatic carcinoma by initiation with N-nitroso-bis(2-oxopropyl)amine and repeated augmentation pressure in hamsters. J. Natl. Cancer Inst. 1988, 80, 1564-1567.
88. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective; AICR: Washington, DC, USA, 2007.
89. Hart, A.R.; Kennedy, H.; Harvey, I. Pancreatic cancer: A review of the evidence on causation. Clin. Gastroenterol. Hepatol. 2008, 6, 275-282.
90. Anderson, K.E.; Sinha, R.; Kulldorff, M.; Gross, M.; Lang, N.P.; Barber, C.; Harnack, L.; DiMagno, E.; Bliss, R.; Kadlubar, F.F. Meat intake and cooking techniques: Associations with pancreatic cancer. Mutat. Res. 2002, 506-507, 225-231.
91. Yoshimoto, M.; Tsutsumi, M.; Iki, K.; Sasaki, Y.; Tsujiuchi, T.; Sugimura, T.; Wakabayashi, K.; Konishi, Y. Carcinogenicity of heterocyclic amines for the pancreatic duct epithelium in hamsters. Cancer Lett. 1999, 143, 235-239.
92. Li, D.; Day, R.S.; Bondy, M.L.; Shinha, R.; Tguyen, N.T.; Evans, D.B.; Abbruzzese, J.L.; Hassan, M.M. Dietary mutagen exposure and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 655-661.
93. Lin, Y.; Kikuchi, S.; Tamakoshi, A.; Yagyu, K.; Obata, Y.; Inaba, Y.; Kurosawa, M.; Kawamura, T.; Motohashi, Y.; Ishibashi, T. Dietary habits and pancreatic cancer risk in a cohort of middle-aged and elderly Japanese. Nutr. Cancer 2006, 56, 40-49.
94. Bravi, F.; Polesel, J.; Bosetti, C.; Talamini, R.; Negri, E.; Dal Maso, L.; Serraino, D.; La Vecchia, C. Dietary intake of selected micronutrients and the risk of pancreatic cancer: An Italian case-control study. Ann. Oncol. 2010, 22, 202-206.
95. Wenger, F.A.; Kilian, M.; Ridders, J.; Stahlknecht, P.; Schimke, I.; Guski, H.; Jacobi, C.A.; Müller, J.M. Influence of antioxidative vitamins A, C and E on lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Prostaglandins Leukot. Essent. Fatty Acids 2001, 65, 165-171.
96. Wolff, R.A. Chemoprevention for pancreatic cancer. Int. J. Gastrointest Cancer 2003, 33, 27-41.
97. Kusama, T.; Mukai, M.; Iwasaki, T.; Tatsuta, M.; Matsumoto, Y.; Akedo, H.; Inoue, M.; Nakamura, H. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002, 122, 308-317.
98. Khurana, V.; Sheth, A.; Caldito, G.; Barkin, J.S. Statins reduce the risk of pancreatic cancer in humans: A case-control study of half a million veterans. Pancreas 2007, 34, 260-265.
99. Bonovas, S.; Filioussi, K.; Sitaras, N.M. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: Evidence from a meta-analysis of 12 studies. Am. J. Gastroenterol. 2008, 103, 2646-2651.
100. Bosetti, C.; La Vecchia, C. Aspirin and cancer risk: A summary review to 2007. Recent Results Cancer Res. 2009, 181, 231-251.
101. Larsson, S.C.; Giovannucci, E.; Bergkvist, L.; Wolk, A. Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: A meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 2561-2564.
102. Bonifazi, M.; Gallus, S.; Bosetti, C.; Polesel, J.; Serraino, D.; Talamini, R.; Negi, E.; La Vecchia, C. Aspirin use and pancreatic cancer risk. Eur. J. Cancer Prev. 2010, 19, 352-354.
103. Anderson, K.E.; Johnson, T.W.; Lazovich, D.; Folsom, A.R. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J. Natl. Cancer Inst. 2002, 94, 1168-1171.
104. Schernhammer, E.S.; Kang, J.H.; Chan, A.T.; Michaud, D.S.; Skinner, H.G.; Giovannucci, E.; Colditz, G.A.; Fuchs, C.S. A prospective study of aspirin use and the risk of pancreatic cancer in women. J. Natl. Cancer Inst. 2004, 96, 22-28.
105. Kisfalvi, K.; Eibl, G.; Sinnett-Smith, J.; Rozengurt, E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009, 69, 6539-6545.
106. Feng, Y.H.; Velazquez-Torres, G.; Gully, C.; Chen, J.; Lee, M.H.; Yeung, S.C. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. Cell. Mol. Med. 2010, doi:10.1111/j.1582-4934.2010.01083.x.
107. Li, D.; Yeung, S.C.; Hassan, M.M.; Konopleva, M.; Abbruzzese, J.L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137, 482-488.
108. Lin, Y.; Tamakoshi, A.; Hayakawa, T.; Naruse, S.; Kitagawa, M.; Ohno, Y. Nutritional factors and risk of pancreatic cancer: A population-based case-control study based on direct interview in Japan. J. Gastroenterol. 2005, 40, 297-301.
109. Takeuchi, T.; Nakao, M.; Nomura, K.; Yano, E. Association of metabolic syndrome with smoking and alcohol intake in Japanese men. Nicotine Tob. Res. 2009, 11, 1093-1098.
110. Ashakumary, L.; Vijayammal, P.L. Effect of nicotine on lipoprotein metabolism in rats. Lipids 1997, 32, 311-315.
111. Hill, M.J.; Metcalfe, D.; McTernan, P.G. Obesity and diabetes: Lipids, 'nowhere to run to'. Clin. Sci. (Lond) 2009, 116, 113-123.
112. Hillon, P.; Guiu, B.; Vincent, J.; Petit, J.M. Obesity, type 2 diabetes and risk of digestive cancer. Gastroenterol. Clin. Biol. 2010, 34, 529-533.
113. Takeuchi, Y.; Takahashi, M.; Sakano, K.; Mutoh, M.; Niho, N.; Yamamoto, M.; Sato, H.; Sugimura, T.; Wakabayashi, K. Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferatoractivated receptor gamma. Carcinogenesis 2007, 28, 1692-1696.
114. Schneider, M.B.; Matsuzaki, H.; Haorah, J.; Ulrich, A.; Standop, J.; Ding, X.Z.; Adrian, T.E.; Pour, P.M. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001, 120, 1263-1270.
115. Staels, B. Metformin and pioglitazone: Effectively treating insulin resistance. Curr. Med. Res. Opin. 2006, 22 (Suppl. 2), S27-S37.
116. Tucker, O.N.; Dannenberg, A.J.; Yang, E.K.; Zhang, F.; Teng, L.; Daly, J.M.; Soslow, R.A.; Masferrer, J.L.; Woerner, B.M.; Koki, A.T.; Fahey, T.J. 3rd. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999, 59, 987-990.
117. Molina, M.A.; Sitja-Arnau, M.; Lemoine, M.G.; Frazier, M.L.; Sinicrope, F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999, 59, 4356-4362.
118. Furukawa, F.; Nishikawa, A.; Lee, I.S.; Kanki, K.; Umemura, T.; Okazaki, K.; Kawamori, T.; Wakabayashi, K.; Hirose, M. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int. J. Cancer 2003, 104, 269-273.
119. Takahashi, M.; Furukawa, F.; Toyoda, K.; Sato, H.; Hasegawa, R.; Imaida, K.; Hayashi, Y. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990, 11, 393-395.
120. Nishikawa, A.; Furukawa, F.; Lee, I.S.; Tanaka, T.; Hirose, M. Potent chemopreventive agents against pancreatic cancer. Curr. Cancer Drug Targets 2004, 4, 373-384.
121. Ouyang, N.; Williams, J.L.; Tsioulias, G.J.; Gao, J.; Iatropoulos, M.J.; Kopelovich, L.; Kashfi, K.; Rigas, B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 2006, 66, 4503-4511.
122. Schuller, H.M.; Zhang, L.; Weddle, D.L.; Castonguay, A.; Walker, K.; Miller, M.S. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J. Cancer Res. Clin. Oncol. 2002, 128, 525-532.
123. Fendrich, V.; Chen, N.M.; Neef, M.; Waldmann, J.; Buchholz, M.; Feldmann, G.; Slater, E.P.; Maitra, A.; Bartsch, D.K. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010, 59, 630-637.
124. Funahashi, H.; Satake, M.; Dawson, D.; Huynh, N.-A.; Reber, H.A.; Hines, O.J.; Eibl, G. Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007, 67, 7068-7071.
125. Hennig, R.; Ding, X.Z.; Tong, W.G.; Schneider, M.B.; Standop, J.; Friess, H.; Büchler, M.W.; Pour, P.M.; Adrian, T.E. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 2002, 161, 421-428.
126. Hennig, R.; Grippo, P.; Ding, X.Z.; Rao, S.M.; Buchler, M.W.; Friess, H.; Talamonti, M.S.; Bell, R.H.; Adrian, T.E. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 2005, 65, 6011-6016.
127. Wenger, F.A.; Kilian, M.; Bisevac, M.; Khodadayan, C.; von Seebach, M.; Schimke, I.; Guski, H.; Müller, J.M. Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. Clin. Exp. Metastasis 2002, 19, 681-687.
128. Vickers, S.M.; MacMillan-Crow, L.A.; Green, M.; Ellis, C.; Thompson, J.A. Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch. Surg. 1999, 134, 245-251.
129. Kong, G.; Kim, E.K.; Kim, W.S.; Lee, K.T.; Lee, Y.W.; Lee, J.K.; Paik, S.W.; Rhee, J.C. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J. Gastroenterol. Hepatol. 2002, 17, 914-921.
130. Franco, L.; Doria, D.; Bertazzoni, E.; Benini, A.; Bassi, C. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer. Prostaglandins Other Lipid Mediat. 2004, 73, 51-58.
131. Takahashi, M.; Kitahashi, T.; Ishigamori, R.; Mutoh, M.; Komiya, M.; Sato, H.; Kamanaka, Y.; Naka, M.; Maruyama, T.; Sugimura, T.; Wakabayashi, K. Increased expression of inducible nitric oxide synthase (iNOS) in N-nitrosobis(2-oxopropyl)amine-induced hamster pancreatic carcinogenesis and prevention of cancer development by ONO-1714, an iNOS inhibitor. Carcinogenesis 2008, 29, 1608-1613.
132. Takahashi, M.; Mutoh, M.; Shoji, Y.; Kamanaka, Y.; Naka, M.; Maruyama, T.; Sugimura, T.; Wakabayashi, K. Transfection of K-rasAsp12 cDNA markedly elevates IL-1beta-and lipopolysaccharide-mediated inducible nitric oxide synthase expression in rat intestinal epithelial cells. Oncogene 2003, 22, 7667-7676.
133. Koshiba, T.; Hosotani, R.; Wada, M.; Miyamoto, Y.; Fujimoto, K.; Lee, J.U.; Doi, R.; Arii, S.; Imamura, M. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998, 82, 642-650.
134. Kilian, M.; Gregor, J.I.; Heukamp, I.; Hanel, M.; Ahlgrimm, M.; Schimke, I.; Kristiansen, G.; Ommer, A.; Walz, M.K.; Jacobi, C.A.; Wenger, F.A. Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: Inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75, 429-434.
135. Nakamura, H.; Nishikawa, A.; Furukawa, F.; Kasahara, K.; Miyauchi, M.; Son, H.Y.; Hirose, M. Inhibitory effects of protocatechuic acid on the post-initiation phase of hamster pancreatic carcinogenesis induced by N-nitrosobis(2-oxopropyl)amine. Anticancer Res. 2000, 20, 3423-3427.
136. Hiura, A.; Tsutsumi, M.; Satake, K. Inhibitory effect of green tea extract on the process of pancreatic carcinogenesis induced by N-nitrosobis-(2-oxypropyl)amine (BOP) and on tumor promotion after transplantation of N-nitrosobis-(2-hydroxypropyl)amine (BHP)-induced pancreatic cancer in Syrian hamsters. Pancreas 1997, 15, 272-277.
137. Mizumoto, K.; Ito, S.; Kitazawa, S.; Tsutsumi, M.; Denda, A.; Konishi, Y. Inhibitory effect of butylated hydroxyanisole administration on pancreatic carcinogenesis in Syrian hamsters initiated with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1989, 10, 1491-1494.
138. Yokomatsu, H.; Hiura, A.; Tsutsumi, M.; Satake, K. Inhibitory effect of sarcophytol A on pancreatic carcinogenesis after initiation by N-nitrosobis(2-oxypropyl)amine in Syrian hamsters. Pancreas 1996, 13, 154-159.
139. Furukawa, F.; Nishikawa, A.; Lee, I.S.; Son, H.Y.; Nakamura, H.; Miyauchi, M.; Takahashi, M.; Hirose, M. Inhibition by methionine of pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl) amine. Cancer Lett. 2000, 152, 163-167.
140. Nishikawa, A.; Furukawa, F.; Uneyama, C.; Ikezaki, S.; Tanakamaru, Z.; Chung, F.L.; Takahashi, M.; Hayashi, Y. Chemopreventive effects of phenethyl isothiocyanate on lung and pancreatic tumorigenesis in N-nitrosobis(2-oxopropyl)amine-treated hamsters. Carcinogenesis 1996, 17, 1381-1384.
141. Nishikawa, A.; Lee, I.S.; Uneyama, C.; Furukawa, F.; Kim, H.C.; Kasahara, K.; Huh, N.; Takahashi, M. Mechanistic insights into chemopreventive effects of phenethyl isothiocyanate in N-nitrosobis(2-oxopropyl)amine-treated hamsters. Jpn. J. Cancer Res. 1997, 88, 1137-1142.
142. Nishikawa, A.; Furukawa, F.; Kasahara, K.; Tanakamaru, Z.; Miyauchi, M.; Nakamura, H.; Ikeda, T.; Imazawa, T.; Hirose, M. Failure of phenethyl isothiocyanate to inhibit hamster tumorigenesis induced by N-nitrosobis(2-oxopropyl)amine when given during the post-initiation phase. Cancer Lett. 1999, 141, 109-115.
143. Nishikawa, A.; Furukawa, F.; Ikezaki, S.; Tanakamaru, Z.Y.; Chung, F.L.; Takahashi, M.; Hayashi, Y. Chemopreventive effects of 3-phenylpropyl isothiocyanate on hamster lung tumorigenesis initiated with N-nitrosobis(2-oxopropyl)amine. Jpn. J. Cancer Res. 1996, 87, 122-126.
144. Son, H.Y.; Nishikawa, A.; Furukawa, F.; Lee, I.S.; Ikeda, T.; Miyauchi, M.; Nakamura, H.; Hirose, M. Modifying effects of 4-phenylbutyl isothiocyanate on N-nitrosobis(2-oxopropyl)amine-induced tumorigenesis in hamsters. Cancer Lett. 2000, 160, 141-147.
145. Kuroiwa, Y.; Nishikawa, A.; Kitamura, Y.; Kanki, K.; Ishii, Y.; Umemura, T.; Hirose, M. Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. Cancer Lett. 2006, 241, 275-280.
146. Furukawa, F.; Nishikawa, A.; Chihara, T.; Shimpo, K.; Beppu, H.; Kuzuya, H.; Lee, I.S.; Hirose, M. Chemopreventive effects of Aloe arborescens on N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Cancer Lett. 2002, 178, 117-122.
147. Clapper, M.L.; Wood, M.; Leahy, K.; Lang, D.; Miknyoczki, S.; Ruggeri, B.A. Chemopreventive activity of Oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters. Carcinogenesis 1995, 16, 2159-2165.
148. Askari, M.D.; Tsao, M.S.; Schuller, H.M. The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. J. Cancer Res. Clin. Oncol. 2005, 131, 639-648.
149. Schuller, H.M.; Al-Wadei, H.A. Neurotransmitter receptors as central regulators of pancreatic cancer. Future Oncol. 2010, 6, 221-228.
150. Al-Wadei, H.A.; Al-Wadei, M.H.; Schuller, H.M. Prevention of pancreatic cancer by the betablocker propranolol. Anticancer Drugs. 2009, 20, 477-482.
151. Arafat, H.A.; Gong, Q.; Chipitsyna, G.; Rizvi, A.; Saa, C.T.; Yeo, C.J. Antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J. Am. Coll. Surg. 2007, 204, 996-1005.
152. Mohammed, A.; Janakiram, N.B.; Li, Q.; Madka, V.; Ely, M.; Lightfoot, S.; Crawford, H.; Steele, V.E.; Rao, C.V. The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev. Res. (Phila) 2010, 3, 1417-1426.
153. Morton, J.P.; Karim, S.A.; Graham, K.; Timpson, P.; Jamieson, N.; Athineos, D.; Doyle, B.; McKay, C.; Heung, M.Y.; Oien, K.A.; Frame, M.C.; Evans, T.R.; Sansom, O.J.; Brunton, V.G. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2010, 139, 292-303.
154. Liby, K.T.; Royce, D.B.; Risingsong, R.; Williams, C.R.; Maitra, A.; Hruban, R.H.; Sporn, M.B. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev. Res. 2010, 3, 1427-1434.
155. Grippo, P.J.; Tuveson, D.A. Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev. Res. 2010, 3, 1382-1387.